BioMarin Pharmaceutical, Amicus Therapeutics deal gets early termination from US FTC
MLex Summary: BioMarin Pharmaceutical Inc.'s $4.8 billion acquisition of Amicus Therapeutics received approval in the US through an early termination by the US Federal Trade Commission, the agency announced. The Hart-Scott-Rodino...To view the full article, register now.
Already a subscriber? Click here to view full article